CD274 and melanoma: Immune checkpoints blockade with anti-PD-1/PD-L1 antibodies have been successfully utilized in the treatment of various cancers such as melanoma (9), non–small cell lung cancer (10), bladder carcinoma (11), Hodgkin’s lymphoma (12), and Merkel cell carcinoma (13).